Allergan Announces FDA Acceptance of New Drug Application for Ubrogepant for the Acute Treatment of Migraine
Go back to Allergan Announces FDA Acceptance of New Drug Application for Ubrogepant for the Acute Treatment of Migraine| Allergan Inc (NYSE: AGN) | Delayed: 193.02 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $193.02 | 52 Week High | $322.68 | |||
| Open | $15.33 | 52 Week Low | $186.34 | |||
| Day High | $193.02 | P/E | 45.96 | |||
| Day Low | $193.02 | EPS | $4.20 | |||
| Volume | 43,377 | |||||
